Barclays Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)

Barclays analyst Gena Wang maintained a Hold rating on Beam Therapeutics (BEAMResearch Report) on February 28 and set a price target of $80.00. The company’s shares closed last Tuesday at $73.50.

According to, Wang is a 5-star analyst with an average return of 17.0% and a 47.8% success rate. Wang covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Arcturus Therapeutics, and Sangamo Biosciences.

Currently, the analyst consensus on Beam Therapeutics is a Strong Buy with an average price target of $132.86, which is a 70.8% upside from current levels. In a report issued on February 28, J.P. Morgan also maintained a Hold rating on the stock with a $110.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $138.52 and a one-year low of $56.34. Currently, Beam Therapeutics has an average volume of 867.3K.

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BEAM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Read More on BEAM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More